G-CSF Limitations: These agents essentially overstimulate a bone marrow that is already damaged by chemotherapy. Furthermore, ...
Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to ...
Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to ...
The GOG 3026 trial demonstrated that ribociclib and letrozole combination therapy achieved a 31% response rate and 84% ...
This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD, ...
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...
Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...
Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results